Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sul-Hee | - |
dc.contributor.author | Bae, Youin | - |
dc.contributor.author | Park, Young-Lip | - |
dc.date.accessioned | 2022-11-29T06:41:16Z | - |
dc.date.available | 2022-11-29T06:41:16Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21857 | - |
dc.description.abstract | Atopic dermatitis (AD) is characterized by chronic, relapsing, pruritic inflammatory skin disease. Adiponectin has been reported to have anti-inflammatory effects not only on metabolic disorders but also on various inflammatory disorders. The study aimed to validate adiponectin as a potential biomarker for AD disease severity and treatment response. Seventy-five patients with AD and 28 healthy volunteers were enrolled in the study. Patient information, including Eczema Area and Severity Index (EASI) scores and pruritus numeric rating scales (NRSs), were collected. An enzyme linked immunosorbent assay (ELISA) was conducted to measure levels of serum adiponectin. Additionally, sera of patients treated with dupilumab were collected and measured at 16 and 52 weeks from baseline. Serum adiponectin levels were significantly lower in moderate and severe AD patients than in the control and mild AD patients. Serum adiponectin level was negatively correlated with the EASI score and pruritus NRS. However, no significant changes were observed according to biologic treatment for AD. Low serum adiponectin levels are associated with moderate to severe AD, suggesting a potential role for adiponectin as a biomarker for severity assessment of AD. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm11216255 | - |
dc.identifier.wosid | 000881169600001 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.11, no.21 | - |
dc.citation.title | Journal of Clinical Medicine | - |
dc.citation.volume | 11 | - |
dc.citation.number | 21 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | PSORIATIC PATIENTS | - |
dc.subject.keywordPlus | LEPTIN | - |
dc.subject.keywordPlus | SEVERITY | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordAuthor | adiponectin | - |
dc.subject.keywordAuthor | atopic dermatitis | - |
dc.subject.keywordAuthor | biomarker | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.